ArticleExperimental and therapeutic medicine2015
Antiproliferative effect and characterization of a novel antifungal peptide derived from human Chromogranin A.
Article in Experimental and therapeutic medicine, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 23 citations in OpenAlex.
- Exploring therapeutic avenues: mesenchymal stem/stromal cells and exosomes in confronting enigmatic biofilm-producing fungi.Archives of microbiology · 2023Review
- Antimicrobial Peptides with Anti-International journal of molecular sciences · 2022Review
- Identification of a New Antifungal Peptide W1 From a MarineFrontiers in microbiology · 2022Article
- Design, Dimerization, and Recombinant Production of MCh-AMP1-Derived Peptide inFrontiers in fungal biology · 2021Article
- Characterization, Biological Activity, and Mechanism of Action of a Plant-Based Novel Antifungal Peptide, Cc-AFP1, Isolated FromFrontiers in cellular and infection microbiology · 2021Article
- Expression of chromogranin A-derived antifungal peptide CGA-N12 inBioengineered · 2020Article
- CGA-N9, an antimicrobial peptide derived from chromogranin A: direct cell penetration of and endocytosis byThe Biochemical journal · 2019Article
- The Antifungal Peptide MCh-AMP1 Derived FromFrontiers in microbiology · 2019Article
- CGA-N12, a peptide derived from chromogranin A, promotes apoptosis ofThe Biochemical journal · 2018Article
- An insight into new strategies to combat antifungal drug resistance.Drug design, development and therapy · 2018Review
- Design and pharmacodynamics of recombinant NZ2114 histidine mutants with improved activity against methicillin-resistant Staphylococcus aureus.AMB Express · 2017Article
- Toll-like receptor 2 and dectin-1 function as promising biomarker forExperimental and therapeutic medicine · 2017Article
- Protective effect of a novel antifungal peptide derived from human chromogranin a on the immunity of mice infected with Candida krusei.Experimental and therapeutic medicine · 2017Article
- Identification of novel loci affecting circulating chromogranins and related peptides.Human molecular genetics · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
CGA-N46 is a novel antifungal peptide derived from the N-terminus of human Chromogranin A, corresponding to the 31st to 76th amino acids. Further research on its activities and characteristics may be helpful for the application of CGA-N46 in medical or other situations. In the present study, the antifungal spectrum and physicochemical characteristics of CGA-N46 were investigated using an antifungal assay, its antiproliferative effects on cancer and normal cells were assessed using MTT assay and its combinatorial effect with other antibiotics was analyzed using checkerboard analysis. The results showed that CGA-N46 exhibited antifungal activity against the tested
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.